Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03 2022-12-02 pm EST
374.76 USD   +1.20%
12/01Eli Lilly and Co.'s Unit Completes Negotiations With Canadian Drug Accessibility Alliance for Migraine Drug
MT
12/01Lilly Wraps Up Acquisition of Akouos
MT
12/01Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts Eli Lilly's Price Target to $412 From $395, Reiterates Overweight Rating

09/07/2022 | 09:00am EST


ę MT Newswires 2022
All news about ELI LILLY AND COMPANY
12/01Eli Lilly and Co.'s Unit Completes Negotiations With Canadian Drug Accessibility Allian..
MT
12/01Lilly Wraps Up Acquisition of Akouos
MT
12/01Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Dis..
PR
12/01Eli Lilly Says Phase 3 Study of Alzheimer's Disease Drug Candidate Meets All Endpoints
MT
12/01Eli Lilly and Company (NYSE:LLY) completed the acquisition o..
CI
11/30US FDA Cancels Emergency Use Approval For Eli Lilly's COVID-19 Treatment
MT
11/30Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptoma..
PR
11/30Eli Lilly and Company Shares Positive Donanemab Data in First Active Comparator Study i..
CI
11/30FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
RE
11/30Eli Lilly's Bebtelovimab COVID-19 Drug Reportedly Paused by US FDA
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 28 670 M - -
Net income 2022 6 134 M - -
Net Debt 2022 10 503 M - -
P/E ratio 2022 55,8x
Yield 2022 0,99%
Capitalization 356 B 356 B -
EV / Sales 2022 12,8x
EV / Sales 2023 12,1x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 374,76 $
Average target price 371,23 $
Spread / Average Target -0,94%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY34.07%356 089
JOHNSON & JOHNSON4.57%467 679
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774
MERCK & CO., INC.43.58%278 995